SCHEMBL2048237

SCHEMBL2048237

C=Cc1cc2cc(Br)ccc2cc1N(C)C

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.38
NCEH1 Q6PIU2 2/20 0.37
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM1A O60341 1/20 0.34
BACE1 P56817 1/20 0.33
NOS1 P29475 1/20 0.33
METAP2 P50579 1/20 0.33
CSNK2A1 P68400 1/20 0.33
APP P05067 3/20 0.32
LMNA P02545 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
AHR P35869 1/20 0.31
NR4A2 P43354 1/20 0.31
CCR5 P51681 1/20 0.31
PYCR1 P32322 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2042638 0.83 NCEH1 (0.41) CYP2A6NCEH1KDM4EMEN1ALDH1A1
SCHEMBL7921915 0.81 CYP2A6 (0.45) CYP2A6KDM4EALDH1A1BACE1APP
SCHEMBL7526844 0.80 ERN1 (0.34) KDM4EALDH1A1MAPTKMT2AAPP
SCHEMBL27845640 0.80 MAPT (0.39) CYP2A6KDM4EMEN1ALDH1A1MAPT
SCHEMBL7925139 0.80
SCHEMBL7934543 0.73 CYP2A6 (0.38) CYP2A6NCEH1KDM4EMEN1ALDH1A1
SCHEMBL2044950 0.73 KDM4E (0.40) CYP2A6KDM4EMEN1ALDH1A1MAPT
SCHEMBL27845619 0.71 POLB (0.43) CYP2A6NCEH1KDM4EMEN1ALDH1A1
SCHEMBL22339987 0.70 PYCR1 (0.33) ALDH1A1PYCR1
SCHEMBL2050433 0.70 NCEH1 (0.41) CYP2A6NCEH1KDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2331552-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2013-02-27 EP disclosed
EP-2331552-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2013-02-27 EP disclosed
EP-2331552-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2011-06-15 EP disclosed
WO-2010036551-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-04-01 WO disclosed
US-20100080770-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2010-04-01 US disclosed
US-20100080770-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2010-04-01 US disclosed
US-20100080770-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2010-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100080770-A1 Hepatitis C Virus Inhibitors HAVCR2, HCCS, PYGL CYP2A6 334/4885NCEH1 526/4885KDM4E 3825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.